The opportunity
3 billion people globally affected by neurological disease¹ — most diagnosed too late to act. The bottleneck has never been treatment. It has always been detection.
Lecanemab and Donanemab approved for early Alzheimer's. Prasinezumab and GLP-1 candidates in Phase 3 for Parkinson's. Every one of these treatments only works if patients are identified early enough. No cleared, AI-powered diagnostic platform exists to do that at scale. Until now.
The Alzheimer’s Association’s own position is that requiring clinical symptoms to diagnose the disease is inconsistent with how almost every other chronic condition is defined — including cardiovascular disease, cancer and diabetes.² Parkinson’s patients report symptoms for an average of 10.2 years before diagnosis;³ by the time motor signs appear, more than half of dopaminergic neurons are gone.⁴
Neurology waits for damage. Every other specialty measures before it. The cost of inaction is not measured in missed returns. It is measured in lives.
¹ GBD 2021 Nervous System Disorders Collaborators. Global, regional, and national burden of disorders affecting the nervous system, 1990–2021. The Lancet Neurology 2024;23:344–381.
² Sperling RA. Alzheimer’s Disease Begins Years Before Symptoms: Alzheimer’s Association Workgroup, 2026.
³ Gaenslen A, Swid I, Liepelt-Scarfone I, Godau J, Berg D. The patients’ perception of prodromal symptoms before the initial diagnosis of Parkinson’s disease. Movement Disorders 2011.
⁴ Parkinson Disease. StatPearls, NCBI Bookshelf, 2025.
The science
Eye movements are a direct motor output of the brain. Measuring them at millisecond resolution reveals what is happening across multiple neurological systems simultaneously — without imaging, without contrast agents, without a laboratory.
3,000+ peer-reviewed articles support oculomotor assessment as a neurological tool. 60+ publications directly involve Spryson's platform and technology.
The most precise FDA-cleared eye-tracking and vestibular assessment hardware available. Clinical-grade, millisecond resolution, validated across 40 tests and 800+ neurological variables. Not consumer-grade. Not research-only. Cleared for clinical use.
The platform
FDA-cleared hardware. Clinical assessment goggles and a vestibular diagnostic chair — purpose-built, clinical-grade, cleared for point-of-care use. The device captures the signal; the physician interprets it, exactly like an ECG.
AI clinical decision support. Pattern summaries, risk signals, suggested next steps, and structured reports — directly in the physician's workflow. Updated across indications without premarket review.
At-home patient platform. A clinician-prescribed platform that extends neurological monitoring into the patient's home between clinic visits. Spryson owns and manages the hardware; patients subscribe at $200/month. Every assessment adds to the normative dataset — turning ongoing patient care into compounding clinical intelligence.
The product — three tiers, one platform
NeuroAI The assessment platform. Clinical-grade eye-tracking and vestibular measurement — 40 tests, 800+ neurological variables — with AI clinical decision support and structured reporting delivered into the physician’s workflow.
NeuroAI+ The same platform, deployed as a complete clinical program. Adds the FDA-cleared assessment goggles and the NOTC+ rotational chair, clinician training and certification, co-branded marketing support, and access to the Spryson app store — where indication-specific modules are added as each clearance lands. What a clinic buys to run neurological assessment as a service line rather than a test.
NeuroAI Rx The at-home patient device. Prescribed by a clinician and used by the patient between visits — connected to the practice through telehealth, or operating independently. Spryson owns and manages the hardware; the patient subscribes. Every session returns to the platform.
Go-to-market — two channels
Channel A — Indications & pharma. Active discussions with two top-10 pharma companies and two global medical device companies — each positioned to handle sales, distribution, regulatory approvals, and market access across their territories. A single enterprise partnership gets us to global scale without building the infrastructure ourselves.
Indication
Status
Detail
Eye movement & balance
Cleared
Existing platform — 5× FDA clearances
Parkinson's disease
Active
FDA Breakthrough Designation · Q1 2027 FDA meeting
Early Alzheimer's & dementia
Active
510(k) in progress · Year 1
Multiple sclerosis
Active
Pharma outreach Q1 2027 · Year 2
Vestibular migraine · Fall prevention · Dizziness & vertigo · Anxiety & depression
Pipeline
Gen 2 claims · In progress with research partners
15 cleared indications
Pipeline
Target · Year 5
Channel B — Clinical network. Model validated. Now launching across six verticals: clinical neurology, ENT, physical therapy, mental health, eye doctors, and longevity. NeuroAI+ where the chair is required; NeuroAI where the goggles suffice.
Already deployed · 350+ customers across clinical, government and research settings
NASA — assessing astronaut neurological function since 2019.
U.S. Army — assessing neurological function in soldiers suffering from blast concussion.
IndyCar — tracking cognitive function and identifying concussion in professional racing drivers.
Johns Hopkins — identifying and managing vestibular migraine.
U.S. Department of State — neurological assessment of diplomatic personnel presenting with symptoms consistent with Havana syndrome.
Proven · Scaling · Beyond
Proven · 2024–2026
Platform built and deployed
Scalable manufacturing
Reimbursement established
Pioneer network active
Gen 2 FDA claims filed
Scaling · $25M
500+ customers
AI platform launched
Consumer piloted
Rx product initiated
4 international markets
Path to $24M+ ARR
The Vision · Brain health infrastructure
Millions continuously measured
Largest longitudinal brain dataset
Global standard for brain health
AI compounds with every assessment
Measuring the brain across a lifetime
Projections by channel · Year 3
Channel A — Pharma & licensing
Each FDA clearance for a major neurological indication opens a partnership opportunity sized at $1B+ in addressable revenue. Spryson does not need to capture the market — it needs to be the diagnostic infrastructure the market runs on. We target strategic agreements where pharma and device partners commercialise each indication globally. Five indications. Five partnerships. The platform is the asset.
Channel A revenue is not included in our projections. We will not put a number on outcomes we do not fully control. What we will say: a single pharma partnership for one cleared indication would exceed the entire Channel B projection. We are in active discussions on three.
Channel B — Clinical network
NeuroAI+ 200 clinics · $300K · $60M
NeuroAI 600 clinics · $75K · $45M
NeuroAI Rx 800 clinics · $200/mo · 6-month minimum · 150 Rx/clinic · $144M
Projections assume direct patient payment. Spryson holds 16 CPT billing codes — the prerequisite for insurance reimbursement — so payer coverage is upside to these numbers, not built into them.
Combined clinical channel: $249M
These projections are based on a commercial model already validated across 20+ pioneer clinics. We are not projecting a new model. We are scaling a proven one.
The data engine
Spryson builds two datasets, for two different reasons.
Regulatory evidence — small, rigorous, adjudicated studies designed to win FDA clearance across the major neurological indications. This is what makes the platform billable, prescribable, and reimbursable.
Real-world evidence — 200,000 subjects measured in the course of ordinary care. This is what trains the machine learning, surfaces the next indications, and makes the platform improve with every assessment.
The advantage compounds. Every clearance widens what we can measure, every install widens who we measure, and every assessment makes the platform better. A competitor would need our clearances, our installed base, and four years before reaching the starting line.
Flatiron Health proved the model in oncology and sold to Roche for $1.9B. The neurological equivalent does not exist yet.
Investment thesis
Neurological medicine is at the same inflection point oncology was in 2012. The treatments exist. The detection infrastructure does not — yet. Spryson is the only cleared platform positioned to build it.
Approximately $3M in annual revenue from the installed base, with $12–15M projected next year. Commercial expansion has been deliberately constrained while the platform, regulatory portfolio and support infrastructure were built; the installed base is substantially pre-subscription. This is growth capital, not survival capital.
Convertible Note · 8% per annum · 20% conversion discount
Use of proceeds
Commercial scale-up — c.50%. Sales, clinical support and onboarding capacity: the constraint that has held expansion back.
Regulatory expansion — c.30%. Pivotal and signal studies across successive indications.
Data and infrastructure — c.20%. Cohort build, reference database expansion and platform engineering.
Expansion
International markets — expanding into multiple geographic markets with active regulatory pathways.
Indications — neurological disorders number in the hundreds. Continued expansion across the indication spectrum.
Government healthcare — partnering with national health systems to address the coming neurological disease crisis at population scale.
Corporate health — neurological baseline programs for high-performance workforces.
Wellness & longevity — brain performance for clinics and consumers. Subscription model.
